102 related articles for article (PubMed ID: 23085179)
1. Structure-based de novo design of Eya2 phosphatase inhibitors.
Park H; Ryu SE; Kim SJ
J Mol Graph Model; 2012 Sep; 38():382-8. PubMed ID: 23085179
[TBL] [Abstract][Full Text] [Related]
2. Structure-based virtual screening approach to the discovery of novel inhibitors of eyes absent 2 phosphatase with various metal chelating moieties.
Park H; Jung SK; Yu KR; Kim JH; Kim YS; Ko JH; Park BC; Kim SJ
Chem Biol Drug Des; 2011 Oct; 78(4):642-50. PubMed ID: 21777393
[TBL] [Abstract][Full Text] [Related]
3. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
Park H; Bahn YJ; Ryu SE
Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
[TBL] [Abstract][Full Text] [Related]
4. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.
Krueger AB; Dehdashti SJ; Southall N; Marugan JJ; Ferrer M; Li X; Ford HL; Zheng W; Zhao R
J Biomol Screen; 2013 Jan; 18(1):85-96. PubMed ID: 22820394
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent inhibitors of receptor protein tyrosine phosphatase sigma through the structure-based virtual screening.
Park H; Chien PN; Ryu SE
Bioorg Med Chem Lett; 2012 Oct; 22(20):6333-7. PubMed ID: 22989533
[TBL] [Abstract][Full Text] [Related]
6. Identification of potent VHZ phosphatase inhibitors with structure-based virtual screening.
Park H; Park SY; Oh JJ; Ryu SE
J Biomol Screen; 2013 Feb; 18(2):226-31. PubMed ID: 23042075
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.
Anantharajan J; Baburajendran N; Lin G; Loh YY; Xu W; Ahmad NHB; Liu S; Jansson AE; Kuan JWL; Ng EY; Yeo YK; Hung AW; Joy J; Hill J; Ford HL; Zhao R; Keller TH; Kang C
Protein Sci; 2022 Feb; 31(2):422-431. PubMed ID: 34761455
[TBL] [Abstract][Full Text] [Related]
8. Homology modeling and virtual screening approaches to identify potent inhibitors of slingshot phosphatase 1.
Park H; Park SY; Ryu SE
J Mol Graph Model; 2013 Feb; 39():65-70. PubMed ID: 23220283
[TBL] [Abstract][Full Text] [Related]
9. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.
Park H; Jeong Y; Hong S
Bioorg Med Chem Lett; 2012 Jan; 22(2):1027-30. PubMed ID: 22196123
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.
Park H; Jung SK; Jeong DG; Ryu SE; Kim SJ
Bioorg Med Chem Lett; 2008 Apr; 18(7):2250-5. PubMed ID: 18358718
[TBL] [Abstract][Full Text] [Related]
11. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.
Krueger AB; Drasin DJ; Lea WA; Patrick AN; Patnaik S; Backos DS; Matheson CJ; Hu X; Barnaeva E; Holliday MJ; Blevins MA; Robin TP; Eisenmesser EZ; Ferrer M; Simeonov A; Southall N; Reigan P; Marugan J; Ford HL; Zhao R
J Biol Chem; 2014 Jun; 289(23):16349-61. PubMed ID: 24755226
[TBL] [Abstract][Full Text] [Related]
12. Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.
Anantharajan J; Zhou H; Zhang L; Hotz T; Vincent MY; Blevins MA; Jansson AE; Kuan JWL; Ng EY; Yeo YK; Baburajendran N; Lin G; Hung AW; Joy J; Patnaik S; Marugan J; Rudra P; Ghosh D; Hill J; Keller TH; Zhao R; Ford HL; Kang C
Mol Cancer Ther; 2019 Sep; 18(9):1484-1496. PubMed ID: 31285279
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of rapamycin (mTOR).
Park H; Choe H; Hong S
Bioorg Med Chem Lett; 2014 Feb; 24(3):835-8. PubMed ID: 24393580
[TBL] [Abstract][Full Text] [Related]
14. Structure-based virtual screening approach to the discovery of novel PTPMT1 phosphatase inhibitors.
Park H; Kim SY; Kyung A; Yoon TS; Ryu SE; Jeong DG
Bioorg Med Chem Lett; 2012 Jan; 22(2):1271-5. PubMed ID: 22115589
[TBL] [Abstract][Full Text] [Related]
15. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
Park H; Kim S; Kim YE; Lim SJ
ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
Park H; Choi H; Hong S; Kim D; Oh DS; Hong S
Bioorg Med Chem Lett; 2011 Apr; 21(7):2021-4. PubMed ID: 21354792
[TBL] [Abstract][Full Text] [Related]
17. Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors.
Park H; Li M; Choi J; Cho H; Ham SW
Bioorg Med Chem Lett; 2009 Aug; 19(15):4372-5. PubMed ID: 19500977
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening.
Park H; Bahn YJ; Jung SK; Jeong DG; Lee SH; Seo I; Yoon TS; Kim SJ; Ryu SE
J Med Chem; 2008 Sep; 51(18):5533-41. PubMed ID: 18714978
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of 2-(arylsulfonyl)oxiranes as cell-permeable covalent inhibitors of protein tyrosine phosphatases.
Dana D; Das TK; Kumar I; Davalos AR; Mark KJ; Ramai D; Chang EJ; Talele TT; Kumar S
Chem Biol Drug Des; 2012 Oct; 80(4):489-99. PubMed ID: 22726577
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel BRAF kinase inhibitors with structure-based virtual screening.
Park H; Choi H; Hong S; Hong S
Bioorg Med Chem Lett; 2011 Oct; 21(19):5753-6. PubMed ID: 21873050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
